Therapeutic plasma exchange in rheumatic diseases: a university hospital experience

Córdoba, Juan Pablo; Larrarte, Carolina; Estrada, Cristina; Fernández-Ávila, Daniel G.

doi:10.1016/j.rbre.2017.01.003

Revista Brasileira de Reumatologia (English Edition)

2017

DOI: 10.1016/j.rbre.2017.01.003

|View full text |Cite

Therapeutic plasma exchange in rheumatic diseases: a university hospital experience

Juan Pablo Córdoba

Carolina Larrarte

Cristina Estrada

et al.

Abstract: TPE is a therapeutic alternative that is needed for the management of patients with rheumatic diseases with renal involvement and those who are refractory to conventional management. Our clinical results were in agreement with the global literature.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] Since the first use by Abel et al 4 in 1914, TPE has been widely applied in numerous conditions, including neurological, hematological, nephrological, dermatological, and even rheumatic disorders. [5][6][7][8][9][10] It is widely accepted that the development of most rheumatic diseases are mainly mediated by disordered immune regulations and production of various profile autoantibodies. 11 Consequently, it is of great significance to alleviate the symptoms and improve the prognosis for rheumatic diseases via eliminating harmful substances from blood, although the specific pathogenesis of majority of those entities have been not clearly elucidated, yet.…”

mentioning

confidence: 99%

Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma

2021

View full text Add to dashboard Cite

Objectives: In this study, we aimed to assess the value of therapeutic plasma exchange (TPE) in the treatment of rheumatic diseases and compare the safety of different replacement fluids used in TPE. Patients and methods: A total of 727 TPE procedures in 285 patients (57 males, 228 females; mean age: 39.7±15.4 years; range, 13 to 79 years) with rheumatic diseases between January 2011 and February 2019 were retrospectively analyzed. Data including demographic and clinical characteristics of the patients were recorded. Treatment response to TPE and adverse events were evaluated in all patients. Results: Indications for TPE included 13 different disorders, with the majority being systemic lupus erythematosus (up to 50%). The mean number of TPE sessions was 2.55±1.00 per patient and the mean exchange plasma volume was 2,270±256 mL per session. Combined plasma and albumin was the most frequently used replacement fluid (69.5%), followed by albumin and plasma in 20.5% and 10.0% of episodes, respectively. Up to 73.7% (210/285) patients achieved clinical improvement after TPE treatment. Adverse events occurred in 15.1% (110/727) of all the procedures, and allergic reaction (34.5%) was the most common event. The overall incidence rate of complication was similar among the three types of replacement fluids (p=0.214). Conclusion: Based on our study results, TPE is an invasive, but safe, useful and, sometimes, essential tool with an acceptable risk/benefit ratio for most rheumatic diseases. Albumin can be used as a feasible substitute for plasma in case of shortage of blood resources.

show abstract

mentioning

confidence: 99%

Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma

2021

View full text Add to dashboard Cite

show abstract

Clinical characteristics and outcomes of patients with inflammatory and autoimmune rheumatological diseases admitted for intensive care in Colombia

Fernández-Ávila,

Vargas-Vanegas,

Galindo-Rozo

et al. 2023

Reumatismo

View full text Add to dashboard Cite

Objective. Contemporary studies reporting outcomes of critical care in patients with inflammatory and autoimmune rheumatological diseases are scarce. This study describes 15 years of experience from 2005-2019 in a Colombian referral hospital. Methods. This observational, descriptive, consecutive case series study was performed on adult patients with inflammatory and autoimmune rheumatic diseases who were admitted to the intensive care unit (ICU) of the San Ignacio University Hospital in Bogotá (Colombia), from January 1, 2005, to December 21, 2019. We describe the sociodemographic characteristics, admission causes and criteria, lengths of stay, immunosuppressive treatment, systemic support, and mortality. Results. The study included 300 patients with a median age of 48 years [interquartile range (IQR) 31-62 years], predominantly female (76%). Disease exacerbations (30%), infections (17.6%), and cardiovascular diseases (15%) were the main causes of admission. Respiratory failure (23%) most commonly caused by septic shock (24%) was the principal indication for intensive care admission. The most frequent infections were community-acquired pneumonia (11.6%) and soft-tissue infections (9%). In 40.3% of patients, inotropic and vasopressor support was required. The median length of stay was 4 days (IQR 2-8), and global mortality was 21.6%. Conclusions. Rheumatic diseases in the ICU are still associated with high morbidity and mortality. Patients with inflammatory and autoimmune rheumatic diseases require a meticulous clinical approach, strict clinical monitoring, frequent assessment of complications, evaluation of systemic support needs, and specific management.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Therapeutic plasma exchange in rheumatic diseases: a university hospital experience

Abstract: TPE is a therapeutic alternative that is needed for the management of patients with rheumatic diseases with renal involvement and those who are refractory to conventional management. Our clinical results were in agreement with the global literature.

Cited by 2 publications

References 20 publications

Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma

Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma

Clinical characteristics and outcomes of patients with inflammatory and autoimmune rheumatological diseases admitted for intensive care in Colombia

Contact Info

Product

Resources

About